BridgeBio Pharma (BBIO) Retained Earnings (2018 - 2026)

BridgeBio Pharma has reported Retained Earnings for 9 years, with the latest figure at -$4.0 billion in Q1 2026.

• Quarterly Retained Earnings changed N/A year-over-year to -$4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 billion (changed N/A YoY) and the FY2025 annual result came in at $2.1 billion, up 25720475.0% from the prior year.
• Retained Earnings declined to -$4.0 billion in Q1 2026 per BBIO's latest filing, from $2.1 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $2.1 billion in Q4 2025 and troughed at -$4.0 billion in Q1 2026.
• A 5-year average of -$1.5 billion and a median of -$1.7 billion in 2022 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 25720475.0% in 2025, down 86139600.0% in 2025.
• Over 5 years, Retained Earnings stood at -$328000.0 in 2022, then slumped by 780540.55% to -$2.6 billion in 2023, then soared by 100.0% to $8000.0 in 2024, then surged by 25720475.0% to $2.1 billion in 2025, then sank by 293.68% to -$4.0 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$4.0 billion, $2.1 billion, and -$3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.